Earnings summaries and quarterly performance for Medpace Holdings.
Executive leadership at Medpace Holdings.
Board of directors at Medpace Holdings.
Research analysts who have asked questions during Medpace Holdings earnings calls.
Ann Hynes
Mizuho Financial Group
4 questions for MEDP
Charles Rhyee
TD Cowen
4 questions for MEDP
Eric Coldwell
Robert W. Baird & Co.
4 questions for MEDP
Jailendra Singh
Truist Securities
4 questions for MEDP
Justin Bowers
Deutsche Bank AG
4 questions for MEDP
Max Smock
William Blair & Company
4 questions for MEDP
Daniel Leonard
Stifel Financial Corp.
3 questions for MEDP
David Windley
Jefferies Financial Group Inc.
3 questions for MEDP
Michael Cherny
Leerink Partners
2 questions for MEDP
Dave Windley
Jefferies LLC
1 question for MEDP
Kyle Crews
UBS
1 question for MEDP
Luke Sergott
Barclays
1 question for MEDP
Recent press releases and 8-K filings for MEDP.
- Medpace Holdings, Inc. reported Q3 2025 revenue of $659.9 million, a 23.7% increase from the prior-year period, with GAAP net income of $111.1 million and $3.86 per diluted share.
- Net new business awards for Q3 2025 increased 47.9% year-over-year to $789.6 million, resulting in a net book-to-bill ratio of 1.20x.
- The company's backlog as of September 30, 2025, grew 2.5% to $3,000.6 million.
- Medpace forecasts full year 2025 revenue between $2.480 billion and $2.530 billion and diluted earnings per share in the range of $14.60 to $14.86.
- For the nine months ended September 30, 2025, the company repurchased 2,961,924 shares for a total of $912.9 million.
Quarterly earnings call transcripts for Medpace Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more